A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

NCT00121017 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infection
Hepatitis C

Interventions

DRUG: Kaletra (lopinavir/ritonavir)
DRUG: Sustiva (efavirenz)
DRUG: Truvada (emtricitabine/tenofovir disoproxil fumarate)

Sponsor

Abbott